- Rekrutierung läuftA Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAPdeletion
(Master Protocol)Molekulare Marker - Rekrutierung läuftA Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)Molekulare Marker
- Rekrutierung läuftA Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects with Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non- Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713Molekulare Marker
- Rekrutierung läuft
A First – in Human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 764532 administered by repeated intravenous infusions in patients with Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3
Molekulare Marker - Rekrutierung läuft
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors
EUDRA-CT Nummer geändert 18.12.2023
von 2021-001188-26 auf 2023-503651-10-00
Indikationen- Brustkrebs (Mammakarzinom)
- Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)
- Gebärmutterhalskrebs (Zervixkarzinom)
- Eierstockkrebs (Ovarialkarzinom)
- Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)
- Nierenzellkarzinom
- Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)
- Magenkarzinom
- Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)
- Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)
- Bauchspeicheldrüsenkrebs (Pankreaskarzinom)
- Lungentumoren
- Nicht-kleinzelliges Bronchialkarzinom (NSCLC)
- Kopf/Hals Tumoren
- Kopf-Hals-Malignome
- Hirntumore (ZNS Tumore)
- Akustikusneurinom (Vestibularis-Schwannom)
- Hauttumoren
- Malignes Melanom
- Rekrutierung läuftA Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plusChemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants withPreviously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell LungCancer with KRAS G12C Mutation (KRYSTAL-4)Molekulare Marker
- Rekrutierung läuftA Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of BMS-986504 Monotherapy in Participants with Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) with Homozygous MTAP Deletion After Progression on Prior Therapies
- Rekrutierung läuftKlinische Plattform zur Erforschung molekularer Veränderung und der Behandlung von Nicht-Kleinzelligem Lungenkrebs
- Rekrutierung läuft
A phase 2b, randomized, blinded, placebo-controlled trial investigating the efficacy and safety of visugromab versus placebo, both in combination with pembrolizumab, pemetrexed, and cis-/carboplatin, in participants with newly diagnosed metastatic non-squamous non-small cell lung cancer (GDFATHER-LUNG-01)
- Rekrutierung läuftA Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)Molekulare Marker